Abstract
76 Adjuvant Durvalumab post chemoradiotherapy in stage III unresectable non-small cell lung cancer: A retrospective review from the University Hospitals Bristol and Weston NHS Foundation Trusts
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
